Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
Kleiner and Perkins provided $100,000 on the May closing, and acquired 20,000 shares of preferred stock from Genentech. [6] Swanson was made the president and treasurer of Genentech, and received a $2,500 per month salary, along with 25,000 shares. [6] This marked the end of Swanson's unemployment, and the beginning of his career at Genentech ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
In February 2015, AMRI acquired SSCI based in West Lafayette, Indiana. SSCI was founded in 1991, providing comprehensive cGMP solid state chemistry research and analytical services to the pharmaceutical industry. Servicing more than 250 customers a year. [25] [26] In July 2015, the company acquired Gadea Pharmaceutical group for $174 million. [27]
In 2014 the drug failed a Phase III trial in prostate cancer, and the company laid off 70% of its employees. [21] In 2015 Genentech and Exelixis won FDA approval for cobimetinib for certain forms of melanoma. [22] In March 2016 Exelixis licensed to Ipsen worldwide rights (outside the US, Canada, and Japan) to market cabozantinib. [23]
Three former Genentech employees have been indicted for funneling trade secrets to biosimilar rival JHL Biotech. In a civil suit, Genentech is suing the employees, JHL, and its founders, who are ...
On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for ...
[9] [10] In addition, according to a Stanford alumni survey conducted in 2011, some 39,900 companies founded by Stanford alumni were active, and companies founded by Stanford alumni altogether generated more than $2.7 trillion in annual revenue and had created 5.4 million jobs, roughly equivalent to the 10th-largest economy in the world (2011).